Shah M.H. Goldner W.S. Benson A.B. et al.

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 19: 839-868Dasari A. Shen C. Halperin D. et al.

Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.

JAMA Oncol. 3: 1335-1342Rindi G. Klimstra D.S. Abedi-Ardekani B. et al.

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Mod Pathol Dec. 31: 1770-1786Nagtegaal I.D. Odze R.D. Klimstra D. et al.

The 2019 WHO classification of tumours of the digestive system.

Histopathology. 76: 182-188Maxwell J.E. O'Dorisio T.M. Howe J.R.

Biochemical diagnosis and preoperative imaging of gastroenteropancreatic neuroendocrine tumors.

Surg Oncol Clin N Am. 25: 171-194Sahani D.V. Bonaffini P.A. Fernández-Del Castillo C. et al.

Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management.

Radiology. 266: 38-61

Standard imaging techniques for neuroendocrine tumors.

Endocrinol Metab Clin North Am. 40 (): 153-162Kuo J.H. Lee J.A. Chabot J.A.

Nonfunctional pancreatic neuroendocrine tumors.

Surg Clin North Am. 94: 689-708Dahdaleh F.S. Lorenzen A. Rajput M. et al.

The value of preoperative imaging in small bowel neuroendocrine tumors.

Ann Surg Oncol. 20: 1912-1917Dromain C. de Baere T. Lumbroso J. et al.

Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.

J Clin Oncol. 23: 70-78

Imaging of neuroendocrine tumors: indications, interpretations, limits, and pitfalls.

Endocrinol Metab Clin North Am. 46: 795-814Shimada K. Isoda H. Hirokawa Y. et al.

Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases.

Eur Radiol. 20: 2690-2698Ba-Ssalamah A. Uffmann M. Saini S. et al.

Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

Eur Radiol. 19: 342-357Giesel F.L. Kratochwil C. Mehndiratta A. et al.

Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.

Eur J Radiol. 81: 2820-2825Park S. Parihar A.S. Bodei L. et al.

Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.

J Nucl Med. 62: 1323-1329

Peptide receptor expression in GEP-NET.

Virchows Arch. 451: S47-S50

NETSPOT (kit for the preparation of gallium Ga-68 DOTATATE injection).

() ()

Drug approval package: Gallium DOTATOC Ga-68.

() ()

Cu-64 DOTATATE (Detectnet™) full prescribing information.

() ()Hope T.A. Bergsland E.K. Bozkurt M.F. et al.

Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors.

J Nucl Med. 59: 66-74

Updates to the appropriate-use criteria for somatostatin receptor PET.

J Nucl Med. 61: 1764Jacobsson H. Larsson P. Jonsson C. et al.

Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET.

Clin Nucl Med. 37: 362-365Delbeke D. Newman G. Deppen S. et al.

68Ga-DOTATATE: significance of uptake in the tail of the pancreas in patients without lesions.

Clin Nucl Med. 44: 851-854Kroiss A. Putzer D. Decristoforo C. et al.

68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.

Eur J Nucl Med Mol Imaging. 40: 514-523Al-Ibraheem A. Bundschuh R.A. Notni J. et al.

Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?.

Eur J Nucl Med Mol Imaging. 38: 2005-2013Krausz Y. Rubinstein R. Appelbaum L. et al.

Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns.

Clin Nucl Med. 37: 57-62Hofman M.S. Lau W.F. Hicks R.J.

Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.

Radiographics. 35: 500-516Lancellotti F. Sacco L. Cerasari S. et al.

Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review.

World J Surg Oncol. 17: 117Shah M. McClelland A. Moadel R. et al.

Splenule disguised as pancreatic mass: elucidated with SPECT liver-spleen scintigraphy.

Clin Nucl Med. 39: e405-e406Belkhir S.M. Archambaud F. Prigent A. et al.

Intrapancreatic accessory spleen diagnosed on radionuclide imaging.

Clin Nucl Med. 34: 642-644Muehler M.R. Rendell V.R. Bergmann L.L. et al.

Ferumoxytol-enhanced MR imaging for differentiating intrapancreatic splenules from other tumors.

Abdom Radiol (Ny). 46: 2003-2013Pfeifer A. Knigge U. Binderup T. et al.

64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-Octreotide in 112 Patients.

J Nucl Med. 56: 847-854Loft M. Carlsen E.A. Johnbeck C.B. et al.

(64)Cu-DOTATATE PET in Patients with neuroendocrine neoplasms: prospective, head-to-head comparison of imaging at 1 hour and 3 hours After Injection.

J Nucl Med. 62: 73-80Delpassand E.S. Ranganathan D. Wagh N. et al.

(64)Cu-DOTATATE PET/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial.

J Nucl Med. 61: 890-896Johnbeck C.B. Knigge U. Loft A. et al.

Head-to-Head Comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.

J Nucl Med. 58: 451-457Kayani I. Bomanji J.B. Groves A. et al.

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

Cancer. 112: 2447-2455Ambrosini V. Kunikowska J. Baudin E. et al.

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

Eur J Cancer Mar. 146: 56-73Bahri H. Laurence L. Edeline J. et al.

High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.

J Nucl Med. 55: 1786-1790Binderup T. Knigge U. Johnbeck C.B. et al.

(18)F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study.

J Nucl Med. 62: 808-815Binderup T. Knigge U. Loft A. et al.

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.

Clin Cancer Res. 16: 978-985Ezziddin S. Adler L. Sabet A. et al.

Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.

J Nucl Med. 55: 1260-1266Rinzivillo M. Partelli S. Prosperi D. et al.

Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms.

Oncologist. 23: 186-192Tang L.H. Untch B.R. Reidy D.L. et al.

Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas.

Clin Cancer Res. 22: 1011-1017Binderup T. Knigge U. Loft A. et al.

Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.

J Nucl Med. 51: 704-712Deroose C.M. Hindie E. Kebebew E. et al.

Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.

J Nucl Med. 57: 1949-1956Has Simsek D. Kuyumcu S. Turkmen C. et al.

Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?.

J Nucl Med. 55: 1811-1817Zhang J. Liu Q. Singh A. et al.

Prognostic Value of (18)F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.

J Nucl Med. 61: 1560-1569Polley M.Y. Leung S.C. McShane L.M. et al.

An international Ki67 reproducibility study.

J Natl Cancer Inst. 105: 1897-1906Singh S. Hallet J. Rowsell C. et al.

Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.

Eur J Surg Oncol. 40: 1517-1522Garin E. Le Jeune F. Devillers A. et al.

Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.

J Nucl Med. 50: 858-864Strosberg J. El-Haddad G. Wolin E. et al.

Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.

N Engl J Med. 376: 125-135Krenning E.P. Valkema R. Kooij P.P. et al.

Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.

Ital J Gastroenterol Hepatol. 31: S219-S223Werner R.A. Solnes L.B. Javadi M.S. et al.

SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework.

J Nucl Med Jul. 59: 1085-1091Hope T.A. Calais J. Zhang L. et al.

(111)In-Pentetreotide Scintigraphy Versus (68)Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.

J Nucl Med Sep. 60: 1266-1269Hicks R.J. Kwekkeboom D.J. Krenning E. et al.

ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues.

Neuroendocrinology. 105: 295-309Hope T.A. Bodei L. Chan J.A. et al.

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy.

J Nucl Med. 61: 222-227Huizing D.M.V. Aalbersberg E.A. Versleijen M.W.J. et al.

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.

Cancer Imaging. 20: 57Gabriel M. Oberauer A. Dobrozemsky G. et al.

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

J Nucl Med. 50: 1427-1434Werner R.A. Ilhan H. Lehner S. et al.

Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy.

Mol Imaging Biol. 21: 582-590Werner R.A. Lapa C. Ilhan H. et al.

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.

Oncotarget. 8: 7039-7049Graf J. Pape U.F. Jann H. et al.

Prognostic Significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE.

Eur J Nucl Med Mol Imaging. 47: 881-894Roll W. Weckesser M. Seifert R. et al.

Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management.

Eur J Nucl Med Mol Imaging. 48: 4016-4027Eisenhauer E.A. Therasse P. Bogaerts J. et al.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Eur J Cancer. 45: 228-247

Li N, Maresh G, Cretcher M, et al., A modern non-SQL approach to radiology-centric search engine design with clinical validation, 2020, arXiv preprint arXiv:2007.02124.